Inhibitor of NF-κB kinases α and β are both essential for high mobility group box 1-mediated chemotaxis

Journal of Immunology

Volumn 184, Issue 8, 2010, Pages 4497-4509

  Penzo, Marianna ^a,c,e,h   Molteni, Raffaella ^a   Suda, Tomomi ^e   Samaniego, Sylvia ^e   Raucci, Angela ^b   Habiel, David M ^f   Miller, Frederick ^f   Jiang, Hui Ping ^g   Li, Jun ^g   Pardi, Ruggero ^a   Palumbo, Roberta ^b   Olivotto, Eleonora ^d   Kew, Richard R ^f   Bianchi, Marco E ^a,b   Marcu, Kenneth B ^a,d,e  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e STONY BROOK UNIVERSITY   (United States)

^f STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P52; TRANSCRIPTION FACTOR RELB; CHUK PROTEIN, MOUSE; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL POLARITY; CHEMOTAXIS; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; TIME; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CELLS, CULTURED; CHEMOTAXIS; FIBROBLASTS; HMGB1 PROTEIN; I-KAPPA B KINASE; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTROPHILS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 77952783551     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903131     Document Type: Article

References (81)

1. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.
2. Bonaldi, T., F. Talamo, P. Scaffidi, D. Ferrera, A. Porto, A. Bachi, A. Rubartelli, A. Agresti, and M. E. Bianchi. 2003. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22: 5551-5560.
3. Lotze, M. T., and K. J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5: 331-342.
4. Bianchi, M. E. 2009. HMGB1 loves company. J. Leukoc. Biol. 86: 573-576.
5. Hori, O., J. Brett, T. Slattery, R. Cao, J. Zhang, J. X. Chen, M. Nagashima, E. R. Lundh, S. Vijay, D. Nitecki, et al. 1995. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem. 270: 25752-25761.
6. Bierhaus, A., P. M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold, D. M. Stern, and P. P. Nawroth. 2005. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83: 876-886.
7. Park, J. S., F. Gamboni-Robertson, Q. He, D. Svetkauskaite, J.-Y. Kim, D. Strassheim, J.-W. Sohn, S. Yamada, I. Maruyama, A. Banerjee, et al. 2006. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290: C917-C924.
8. Yu, M., H. Wang, A. Ding, D. T. Golenbock, E. Latz, C. J. Czura, M. J. Fenton, K. J. Tracey, and H. Yang. 2006. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174-179.
9. Kokkola, R., A. Andersson, G. Mullins, T. Ostberg, C. J. Treutiger, B. Arnold, P. Nawroth, U. Andersson, R. A. Harris, and H. E. Harris. 2005. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61: 1-9.
10. Andersson, U., H. Erlandsson-Harris, H. Yang, and K. J. Tracey. 2002. HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72: 1084-1091.
11. Herold, K., B. Moser, Y. Chen, S. Zeng, S. F. Yan, R. Ramasamy, J. Emond, R. Clynes, and A. M. Schmidt. 2007. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 82: 204-212.
12. Palumbo, R., M. Sampaolesi, F. De Marchis, R. Tonlorenzi, S. Colombetti, A. Mondino, G. Cossu, and M. E. Bianchi. 2004. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164: 441-449.
13. Hudson, B. I., A. Z. Kalea, M. Del Mar Arriero, E. Harja, E. Boulanger, V. D'Agati, and A. M. Schmidt. 2008. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 283: 34457-34468.
14. Palumbo, R., B. G. Galvez, T. Pusterla, F. De Marchis, G. Cossu, K. B. Marcu, and M. E. Bianchi. 2007. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J. Cell Biol. 179: 33-40.
15. Palumbo, R., F. De Marchis, T. Pusterla, A. Conti, M. Alessio, and M. E. Bianchi. 2009. Src family kinases are necessary for cell migration induced by extracellular HMGB1. J. Leukoc. Biol. 86: 617-623.
16. Lluis, J. M., F. Buricchi, P. Chiarugi, A. Morales, and J. C. Fernandez-Checa. 2007. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-kappaB via c-SRC and oxidant-dependent cell death. Cancer Res. 67: 7368-7377.
17. Lee, H. S., C. Moon, H. W. Lee, E. M. Park, M. S. Cho, and J. L. Kang. 2007. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. J. Immunol. 179: 7001-7011.
18. Perkins, N. D. 2007. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8: 49-62.
19. Chiu, Y. C., Y. C. Fong, C. H. Lai, C. H. Hung, H. C. Hsu, T. S. Lee, R. S. Yang, W. M. Fu, and C. H. Tang. 2008. Thrombin-induced IL-6 production in human synovial fibroblasts is mediated by PAR1, phospholipase C, protein kinase C alpha, c-Src, NF-kappa B and p300 pathway. Mol. Immunol. 45: 1587-1599.
20. Karin, M., and F. R. Greten. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5: 749-759.
21. Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25: 280-288.
22. Basak, S., H. Kim, J. D. Kearns, V. Tergaonkar, E. O'Dea, S. L. Werner, C. A. Benedict, C. F. Ware, G. Ghosh, I. M. Verma, and A. Hoffmann. 2007. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128: 369-381.
23. Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-kappaB signaling. Cell 132: 344-362.
24. Yamamoto, Y., and R. B. Gaynor. 2004. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci. 29: 72-79.
25. Scheidereit, C. 2006. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25: 6685-6705.
26. Hansberger, M. W., J. A. Campbell, P. Danthi, P. Arrate, K. N. Pennington, K. B. Marcu, D. W. Ballard, and T. S. Dermody. 2007. IkappaB kinase subunits alpha and gamma are required for activation of NF-kappaB and induction of apoptosis by mammalian reovirus. J. Virol. 81: 1360-1371.
27. Lawrence, T., M. Bebien, G. Y. Liu, V. Nizet, and M. Karin. 2005. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434: 1138-1143.
28. Li, Q., Q. Lu, V. Bottero, G. Estepa, L. Morrison, F. Mercurio, and I. M. Verma. 2005. Enhanced NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 (IKK1). Proc. Natl. Acad. Sci. USA 102: 12425-12430.
29. Liu, B., Y. Yang, V. Chernishof, R. R. Loo, H. Jang, S. Tahk, R. Yang, S. Mink, D. Shultz, C. J. Bellone, et al. 2007. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 129: 903-914.
30. Bonizzi, G., M. Bebien, D. C. Otero, K. E. Johnson-Vroom, Y. Cao, D. Vu, A. G. Jegga, B. J. Aronow, G. Ghosh, R. C. Rickert, and M. Karin. 2004. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J. 23: 4202-4210.
31. Saitoh, T., M. Nakayama, H. Nakano, H. Yagita, N. Yamamoto, and S. Yamaoka. 2003. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J. Biol. Chem. 278: 36005-36012.
32. Yang, C. H., A. Murti, and L. M. Pfeffer. 2005. Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J. Biol. Chem. 280: 31530-31536.
33. Hu, Y., V. Baud, M. Delhase, P. Zhang, T. Deerinck, M. Ellisman, R. Johnson, and M. Karin. 1999. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284: 316-320.
34. Takeda, K., O. Takeuchi, T. Tsujimura, S. Itami, O. Adachi, T. Kawai, H. Sanjo, K. Yoshikawa, N. Terada, and S. Akira. 1999. Limb and skin abnormalities in mice lacking IKKalpha. Science 284: 313-316.
35. Li, Q., Q. Lu, J. Y. Hwang, D. Büscher, K. F. Lee, J. C. Izpisua-Belmonte, and I. M. Verma. 1999. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13: 1322-1328.
36. Hu, Y., V. Baud, T. Oga, K. I. Kim, K. Yoshida, and M. Karin. 2001. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410: 710-714.
37. Sil, A. K., S. Maeda, Y. Sano, D. R. Roop, and M. Karin. 2004. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 428: 660-664.
38. Descargues, P., A. K. Sil, Y. Sano, O. Korchynskyi, G. Han, P. Owens, X.-J. Wang, and M. Karin. 2008. IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proc. Natl. Acad. Sci. USA 105: 2487-2492.
39. Engel, F. B., M. Schebesta, M. T. Duong, G. Lu, S. Ren, J. B. Madwed, H. Jiang, Y. Wang, and M. T. Keating. 2005. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19: 1175-1187.
40. Badea, T. C., Y. Wang, and J. Nathans. 2003. A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J. Neurosci. 23: 2314-2322.
41. Seibler, J., B. Zevnik, B. Kuter-Luks, S. Andreas, H. Kern, T. Hennek, A. Rode, C. Heimann, N. Faust, G. Kauselmann, et al. 2003. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 31: e12.
42. Feil, R., J. Brocard, B. Mascrez, M. LeMeur, D. Metzger, and P. Chambon. 1996. Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. Sci. USA 93: 10887-10890.
43. T2 recombinases. Nucleic Acids Res. 27: 4324-4327.
44. Clausen, B. E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Förster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8: 265-277.
45. Browning, J. L., K. Miatkowski, I. Sizing, D. Griffiths, M. Zafari, C. D. Benjamin, W. Meier, and F. Mackay. 1996. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J. Exp. Med. 183: 867-878.
46. Massa, P. E., X. Li, A. Hanidu, J. Siamas, M. Pariali, J. Pareja, A. G. Savitt, K. M. Catron, J. Li, and K. B. Marcu. 2005. Gene expression profiling in conjunction with physiological rescues of IKKalpha-null cells with wild type or mutant IKKalpha reveals distinct classes of IKKalpha/NF-kappaB-dependent genes. J. Biol. Chem. 280: 14057-14069.
47. Penzo, M., P. E. Massa, E. Olivotto, F. Bianchi, R. M. Borzi, A. Hanidu, X. Li, J. Li, and K. B. Marcu. 2009. Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1. J. Cell. Physiol. 218: 215-227.
48. 3. Mol. Immunol. 43: 1109-1115.
49. Zigmond, S. H., and J. G. Hirsch. 1973. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J. Exp. Med. 137: 387-410.
50. Boxio, R., C. Bossenmeyer-Pourié, N. Steinckwich, C. Dournon, and O. Nüsse. 2004. Mouse bone marrow contains large numbers of functionally competent neutrophils. J. Leukoc. Biol. 75: 604-611.
51. Zantl, R., U. Rädler, and E. Horn. 2006. Chemotaxis in mu channels. Imaging & Microscopy 8: 30-32.
52. Orlova, V. V., E. Y. Choi, C. Xie, E. Chavakis, A. Bierhaus, E. Ihanus, C. M. Ballantyne, C. G. Gahmberg, M. E. Bianchi, P. P. Nawroth, and T. Chavakis. 2007. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26: 1129-1139.
53. Fleming, T. J., M. L. Fleming, and T. R. Malek. 1993. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151: 2399-2408.
54. May, A. E., S. M. Kanse, L. R. Lund, R. H. Gisler, B. A. Imhof, and K. T. Preissner. 1998. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 188: 1029-1037.
55. Woolf, E., I. Grigorova, A. Sagiv, V. Grabovsky, S. W. Feigelson, Z. Shulman, T. Hartmann, M. Sixt, J. G. Cyster, and R. Alon. 2007. Lymph node chemokines promote sustained T lymphocyte motility without triggering stable integrin adhesiveness in the absence of shear forces. Nat. Immunol. 8: 1076-1085.
56. Heit, B., S. M. Robbins, C. M. Downey, Z. Guan, P. Colarusso, B. J. Miller, F. R. Jirik, and P. Kubes. 2008. PTEN functions to 'prioritize' chemotactic cues and prevent 'distraction' in migrating neutrophils. Nat. Immunol. 9: 743-752.
57. Müller, N., J. van den Brandt, F. Odoardi, D. Tischner, J. Herath, A. Flügel, and H. M. Reichardt. 2008. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J. Clin. Invest. 118: 1405-1416.
58. Li, J., and A. M. Schmidt. 1997. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506.
59. Kalea, A. Z., N. Reiniger, H. Yang, M. Arriero, A. M. Schmidt, and B. I. Hudson. 2009. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 23: 1766-1774.
60. Raucci, A., S. Cugusi, A. Antonelli, S. M. Barabino, L. Monti, A. Bierhaus, K. Reiss, P. Saftig, and M. E. Bianchi. 2008. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22: 3716-3727.
61. Dejardin, E., N. M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, Z. W. Li, M. Karin, C. F. Ware, and D. R. Green. 2002. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17: 525-535.
62. Qing, G., and G. Xiao. 2005. Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J. Biol. Chem. 280: 9765-9768.
63. Horwitz, R., and D. Webb. 2003. Cell migration. Curr. Biol. 13: R756-R759.
64. Ridley, A. J., M. A. Schwartz, K. Burridge, R. A. Firtel, M. H. Ginsberg, G. Borisy, J. T. Parsons, and A. R. Horwitz. 2003. Cell migration: integrating signals from front to back. Science 302: 1704-1709.
65. Dumitriu, I. E., M. E. Bianchi, M. Bacci, A. A. Manfredi, and P. Rovere-Querini. 2007. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81: 84-91.
66. Kishore, N., C. Sommers, S. Mathialagan, J. Guzova, M. Yao, S. Hauser, K. Huynh, S. Bonar, C. Mielke, L. Albee, et al. 2003. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J. Biol. Chem. 278: 32861-32871.
67. Brett, J., A. M. Schmidt, S. D. Yan, Y. S. Zou, E. Weidman, D. Pinsky, R. Nowygrod, M. Neeper, C. Przysiecki, A. Shaw, et al. 1993. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143: 1699-1712.
68. Demling, N., C. Ehrhardt, M. Kasper, M. Laue, L. Knels, and E. P. Rieber. 2006. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 323: 475-488.
69. Qin, Y.-H., S.-M. Dai, G.-S. Tang, J. Zhang, D. Ren, Z.-W. Wang, and Q. Shen. 2009. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J. Immunol. 183: 6244-6250.
70. Sevillano, N., M. D. Girón, M. Salido, A. M. Vargas, J. Vilches, and R. Salto. 2009. Internalization of the receptor for advanced glycation end products (RAGE) is required to mediate intracellular responses. J Biochem 145: 21-30.
71. Riuzzi, F., G. Sorci, and R. Donato. 2006. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem. 281: 8242-8253.
72. Muhammad, S., W. Barakat, S. Stoyanov, S. Murikinati, H. Yang, K. J. Tracey, M. Bendszus, G. Rossetti, P. P. Nawroth, A. Bierhaus, and M. Schwaninger. 2008. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28: 12023-12031.
73. van Zoelen, M. A. D., H. Yang, S. Florquin, J. C. M. Meijers, S. Akira, B. Arnold, P. P. Nawroth, A. Bierhaus, K. J. Tracey, and T. van der Poll. 2009. Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31: 280-284.
74. Campana, L., L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini. 2009. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86: 609-615.
75. Rouhiainen, A., S. Tumova, L. Valmu, N. Kalkkinen, and H. Rauvala. 2007. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 81: 49-58.
76. Tian, J., A. M. Avalos, S.-Y. Mao, B. Chen, K. Senthil, H. Wu, P. Parroche, S. Drabic, D. Golenbock, C. Sirois, et al. 2007. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8: 487-496.
77. Ivanov, S., A.-M. Dragoi, X. Wang, C. Dallacosta, J. Louten, G. Musco, G. Sitia, G. S. Yap, Y. Wan, C. A. Biron, et al. 2007. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110: 1970-1981.
78. Youn, J. H., Y. J. Oh, E. S. Kim, J. E. Choi, and J.-S. Shin. 2008. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J. Immunol. 180: 5067-5074.
79. Sha, Y., J. Zmijewski, Z. Xu, and E. Abraham. 2008. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180: 2531-2537.
80. Urbonaviciute, V., B. G. Fürnrohr, S. Meister, L. Munoz, P. Heyder, F. De Marchis, M. E. Bianchi, C. Kirschning, H. Wagner, A. A. Manfredi, et al. 2008. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205: 3007-3018.
81. Hreggvidsdottir, H. S., T. Ostberg, H. Wähämaa, H. Schierbeck, A.-C. Aveberger, L. Klevenvall, K. Palmblad, L. Ottosson, U. Andersson, and H. E. Harris. 2009. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86: 655-662.